

# **Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2018**

<https://marketpublishers.com/r/SB67288E7A6EN.html>

Date: August 2018

Pages: 103

Price: US\$ 3,500.00 (Single User License)

ID: SB67288E7A6EN

## **Abstracts**

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2018

### **SUMMARY**

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) pipeline Target constitutes close to 23 molecules. Out of which approximately 22 molecules are developed by companies and remaining by the universities/institutes. The latest report Sphingosine 1-Phosphate Receptor 1 - Pipeline Review, H2 2018, outlays comprehensive information on the Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type.

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Sphingosine-1-phosphate receptor 1 (S1P receptor) is a G-protein coupled receptor. Signaling leads to the activation of RAC1, SRC, PTK2/FAK1 and MAP kinases. It plays an important role in cell migration, migration of osteoclast precursor cells, the regulation of bone mineralization and bone homeostasis and in the protection against ventilator-

induced lung injury. It is required for normal chemotaxis toward sphingosine 1-phosphate, normal embryonic heart development and normal cardiac morphogenesis. It inhibits sprouting angiogenesis to prevent excessive sprouting during blood vessel development.

The molecules developed by companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 1, 4, 6, 7 and 1 respectively. Similarly, the universities portfolio in Preclinical stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Immunology, Gastrointestinal, Cardiovascular, Dermatology, Musculoskeletal Disorders and Oncology which include indications Crohn's Disease (Regional Enteritis), Multiple Sclerosis, Rheumatoid Arthritis, Ulcerative Colitis, Autoimmune Disorders, Relapsing Remitting Multiple Sclerosis (RRMS), Inflammation, Psoriasis, Relapsing Multiple Sclerosis (RMS), Secondary Progressive Multiple Sclerosis (SPMS), Arthritis, Atopic Dermatitis (Atopic Eczema), Cardiovascular Disease, Cerebral Aneurysms, Colitis, Dermatomyositis, Encephalomyelitis, Graft Versus Host Disease (GVHD), Inflammatory Bowel Disease, Kidney Transplant Rejection, Plaque Psoriasis (Psoriasis Vulgaris), Primary Biliary Cirrhosis, Rett Syndrome, Skin Ulcers, Stroke and Systemic Lupus Erythematosus.

Furthermore, this report also reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics development with respective active and dormant or discontinued projects. Driven by data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)

The report reviews Sphingosine 1-Phosphate Receptor 1 (Endothelial

Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics and enlists all their major and minor projects

The report assesses Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) -

Overview

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) -

Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) -

Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) -

Companies Involved in Therapeutics Development

Actelion Pharmaceuticals Ltd

Arena Pharmaceuticals Inc

Astellas Pharma Inc

AstraZeneca Plc

Boston Pharmaceuticals Inc

Bristol-Myers Squibb Co

Celgene Corp

GlaxoSmithKline Plc

Idorsia Pharmaceutical Ltd

LG Chem Ltd

Mitsubishi Tanabe Pharma Corp

Novartis AG

Sanofi

Sun Pharma Advanced Research Company Ltd

Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled

Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Drug Profiles

AKP-11 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

amiselimod hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-0028 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

ASP-4058 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BMS-986104 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BOS-173717 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CBP-307 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

cenerimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CP-1050 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

etrasimod arginine - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
fingolimod hydrochloride - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
FP-253 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
LC-510255 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
NIBR-0213 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress

ozanimod hydrochloride - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
ponesimod - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
SAR-247799 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
SCD-044 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
siponimod - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress

## Small Molecule to Agonize S1P1 for Multiple Sclerosis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecule to Agonize S1P1 for Multiple Sclerosis and Rheumatoid Arthritis - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Small Molecule to Antagonize Sphingosine 1 Phosphate Receptor 1 for Oncology - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## ST-968 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

## Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Dormant Products

## Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Discontinued Products

## Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Product Development Milestones

### Featured News & Press Releases

May 11, 2018: Novartis Announces FDA Approval of Gilenya as the First Disease-modifying Therapy for Pediatric Relapsing Multiple Sclerosis

Apr 24, 2018: New Analyses from Pivotal Phase III Trials of Oral Ozanimod in Relapsing Multiple Sclerosis To Be Presented at the 2018 American Academy of Neurology Annual Meeting

Apr 20, 2018: New Novartis analyses at AAN show siponimod's efficacy on disability and cognition in secondary progressive MS patients

Mar 23, 2018: Phase III data in The Lancet show Novartis siponimod significantly improves outcomes in patients with secondary progressive MS

Mar 19, 2018: Arena Pharmaceuticals Reports Positive Phase 2 Results from the OASIS Trial for Etrasimod in Patients with Ulcerative Colitis



Feb 27, 2018: Celgene Provides Regulatory Update on Ozanimod for the Treatment of Relapsing Multiple Sclerosis

Jan 22, 2018: Arena Pharmaceuticals to Host Key Opinion Leader Event on S1P Modulation and Etrasimod in Autoimmune Diseases on January 29 in New York City

Dec 18, 2017: Novartis multiple sclerosis therapy fingolimod granted FDA Breakthrough Therapy designation for pediatric MS

Nov 10, 2017: Arena Pharmaceuticals Completes Full Enrollment in Etrasimod Phase 2 Clinical Study for Ulcerative Colitis

Nov 09, 2017: Ozanimod Successful in Clinical Trials for Multiple Sclerosis

Oct 28, 2017: Novartis PARADIGMS data show children and adolescents with MS had an 82% lower relapse rate with Gilenya vs. interferon beta-1a

Oct 28, 2017: Efficacy and Safety Results from Second Phase III Trial (RADIANCE Part B) of Oral Ozanimod Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

Oct 27, 2017: Efficacy and Safety Results from First Phase III Trial of Oral Ozanimod (SUNBEAM) Versus an Active Comparator in Relapsing Multiple Sclerosis Presented at MSParis2017 - 7th Joint ECTRIMS - ACTRIMS Meeting

Oct 25, 2017: Novartis confirms leadership in multiple sclerosis with scientific advancements and new data presented at ECTRIMS

Oct 25, 2017: Novartis Presents New Data on Siponimod at ECTRIMS

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Indications, H2 2018  
Number of Products under Development by Indications, H2 2018 (Contd.1), H2 2018  
Number of Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018  
Products under Development by Companies, H2 2018 (Contd.1), H2 2018  
Products under Development by Companies, H2 2018 (Contd.2), H2 2018  
Number of Products under Investigation by Universities/Institutes, H2 2018  
Products under Investigation by Universities/Institutes, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Stage and Route of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018  
Pipeline by Actelion Pharmaceuticals Ltd, H2 2018  
Pipeline by Arena Pharmaceuticals Inc, H2 2018  
Pipeline by Astellas Pharma Inc, H2 2018  
Pipeline by AstraZeneca Plc, H2 2018  
Pipeline by Boston Pharmaceuticals Inc, H2 2018  
Pipeline by Bristol-Myers Squibb Co, H2 2018  
Pipeline by Celgene Corp, H2 2018  
Pipeline by GlaxoSmithKline Plc, H2 2018  
Pipeline by Idorsia Pharmaceutical Ltd, H2 2018  
Pipeline by LG Chem Ltd, H2 2018  
Pipeline by Mitsubishi Tanabe Pharma Corp, H2 2018  
Pipeline by Novartis AG, H2 2018  
Pipeline by Sanofi, H2 2018  
Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2018  
Dormant Products, H2 2018  
Dormant Products, H2 2018 (Contd.1), H2 2018  
Dormant Products, H2 2018 (Contd.2), H2 2018  
Discontinued Products, H2 2018

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2018  
Number of Products under Development by Therapy Areas, H2 2018  
Number of Products under Development by Top 10 Indications, H2 2018  
Number of Products by Mechanism of Actions, H2 2018  
Number of Products by Stage and Mechanism of Actions, H2 2018  
Number of Products by Routes of Administration, H2 2018  
Number of Products by Stage and Routes of Administration, H2 2018  
Number of Products by Stage and Molecule Type, H2 2018

### COMPANIES MENTIONED

Actelion Pharmaceuticals Ltd  
Arena Pharmaceuticals Inc  
Astellas Pharma Inc  
AstraZeneca Plc  
Boston Pharmaceuticals Inc  
Bristol-Myers Squibb Co  
Celgene Corp  
GlaxoSmithKline Plc  
Idorsia Pharmaceutical Ltd  
LG Chem Ltd  
Mitsubishi Tanabe Pharma Corp  
Novartis AG  
Sanofi  
Sun Pharma Advanced Research Company Ltd

## I would like to order

Product name: Sphingosine 1-Phosphate Receptor 1 (Endothelial Differentiation G Protein Coupled Receptor 1 or Sphingosine 1 Phosphate Receptor Edg 1 or CD363 or S1PR1) - Pipeline Review, H2 2018

Product link: <https://marketpublishers.com/r/SB67288E7A6EN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/SB67288E7A6EN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:

Last name:

Email:

Company:

Address:

City:

Zip code:

Country:

Tel:

Fax:

Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below

and fax the completed form to +44 20 7900 3970